Galien Golden Jubilee Forum USA 2021

PANEL 5
Oct. 28th, 2021
3PM – 4:15PM


Chair:
Laurie Glimcher, President & CEO, Dana-Farber Cancer Institute

Panelists:
Scott Armstrong, President, Boston Children’s Cancer & Blood Disorders Center; Chairman, Department of Pediatric Oncology, Dana-Farber Cancer Institute
Danny Bar-Zohar,
Global Head of Development, Merck KGaA
Samit Hirawat,
Executive Vice President, Chief Medical Officer, Global Drug Development, Bristol Myers Squibb
William Kaelin,
Sidney Farber Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute
Crystal Mackall,
Ernest & Amelia Gallo Family Professor of Pediatrics & Internal Medicine, Stanford University

PANEL INTROFULL PROGRAM

Chair
Laurie Glimcher
President & CEO
Dana-Farber Cancer Institute


Scott Armstrong
President, Boston Children’s Cancer & Blood Disorders Center;
Chairman, Department of Pediatric Oncology, Dana-Farber Cancer Institute


Danny Bar-Zohar
Global Head of Development
Merck KGaA

Danny Bar-Zohar, MD, is responsible for the strategic leadership of the Clinical Development portfolio at Merck KGaA, Darmstadt, Germany, including all line functions related to Phase I-IV stage. With his teams, Danny focuses on driving the development of assets with transformative potential in immunology, oncology, and immuno-oncology, ensuring great science is translated into the healthcare solutions of tomorrow for patients. He is a member of the Healthcare Executive Committee, which provides the strategic oversight for the overall Healthcare business.

Danny works relentlessly to accelerate bringing cutting-edge medicines to patients, using advanced therapeutic platforms and novel methodologies. He is committed to fostering a culture where bold ideas raise the bar for Drug Development. 

Before joining Merck KGaA, Darmstadt, Germany in November 2021, Danny has 15 years of experience successfully leading mid-and late-stage clinical development from strategy to execution in neuroscience, immunology, oncology and ophthalmology at Teva Pharmaceuticals, Novartis and most recently at the venture capital firm Syncona Investment Management. His visionary and courageous approach has helped to deliver multiple new global therapeutic approvals at both, Teva Pharmaceuticals and Novartis, with the aim to support patients at every stage of their lives.

Danny has a deep knowledge of the international regulatory environment and its requirements with broad dealings with major health authorities. Prior to joining the pharmaceutical industry, Danny spent several years as a general surgeon at the Tel-Aviv Sourasky Medical Center in Israel.


Samit Hirawat
Executive Vice President, Chief Medical Officer, Global Drug Development
Bristol Myers Squibb

As Chief Medical Officer, Global Drug Development, Dr. Samit Hirawat oversees late-stage product development across all therapeutic areas. In this role, Samit and his organization focus on enabling the rapid progression and delivery of late-stage assets, from proof-of-concept to commercialization, through world-class clinical trial design and operations. 

Samit joined BMS in 2019 with extensive drug development experience, most recently serving as Executive Vice President and Head of Oncology Development for Novartis. Previously, he led clinical development programs in multiple indications at PTC Therapeutics and Pfizer/Pharmacia Corporation.

Samit earned his Bachelor of Medicine, Bachelor of Surgery (MBBS) at Sawai Man Singh Medical College in India, and completed his internal medicine residency and medical oncology training at North Shore University Hospital, New York.


William Kaelin
Sidney Farber Professor of Medicine
Harvard Medical School and Dana-Farber Cancer Institute

William Kaelin obtained undergraduate and M.D. degrees from Duke University and completed his internal medicine training at the Johns Hopkins Hospital, where he served as chief medical resident. He was a clinical fellow in medical oncology at the Dana-Farber Cancer Institute and a postdoctoral fellow in the laboratory of David Livingston, during which time he was a McDonnell Scholar.  He is currently the Sidney Farber Professor of Medicine in the Department of Medicine at the Dana-Farber Cancer Institute and the Brigham and Women’s Hospital, Harvard Medical School.  Dr. Kaelin is a member of the American Society of Clinical Investigation, the National Academy of Sciences, the American Academy of Arts and Science and the National Academy of Medicine, and is a Fellow of the AACR Academy and American College of Physicians.  He previously served on the NCI Board of Scientific Advisors, the AACR Board of Trustees and the IOM National Cancer Policy Board. He has received numerous awards including the MSKCC Paul Marks Prize, the AACR Richard and Hinda Rosenthal Prize, a Doris Duke Distinguished Clinical Scientist Award, the Canada International Gairdner International Award, the ASCI Stanley J. Korsmeyer Award, the Scientific Grand Prix of the Foundation Lefoulon-Delalande and the Institute of France, the Albert Lasker Prize, the Helis Award and the Massry Prize. In 2019, Dr. Kaelin received the 2019 Nobel Prize in Physiology or Medicine.


Crystal Mackall
Ernest & Amelia Gallo Family Professor of Pediatrics & Internal Medicine
Stanford University

Crystal L. Mackall, MD is the Ernest and Amelia Gallo Family Professor of Pediatrics and Medicine at Stanford University. She serves as the Founding Director of the Stanford Center for Cancer Cell Therapy, Associate Director of Stanford Cancer Institute, Leader of the Cancer Immunology and Immunotherapy Program, and Director of the Parker Institute for Cancer Immunotherapy at Stanford.   During a 27 year tenure culminating as Chief of the Pediatric Oncology Branch, NCI, and now through the Center for Cancer Cell Therapy at Stanford, she has led an internationally recognized translational research program focused on pediatric immuno-oncology. Dr. Mackall has led numerous first-in-child clinical trials and has incorporated deep biologic endpoints into clinical studies that have furthered our understanding of immunotherapies for children’s cancers. She has published over 185 manuscripts and serves in numerous national leadership positions, including Chair of the NCI Pediatric Cancer Immunotherapy Trial Network, and co-Leader of the St. Baldrick’s-StandUp2Cancer Pediatric Dream Team. She is the recipient of numerous awards and is a member of the American Society of Clinical Investigation and the American Academy of Physicians.